Moderna Inc. (MRNA) — ESG & Values Scores

Environment story

Moderna demonstrates moderate environmental performance with significant gaps in disclosure and climate strategy. No disclosed Scope 1, 2, or 3 emissions data or net-zero target found in filings. The company manufactures mRNA vaccines requiring cold-chain logistics and specialized manufacturing infrastructure with material energy demands. Manufacturing facilities in Australia, Canada, and UK are recently operational but no published renewable energy commitments. No material environmental controversies or litigation identified in provided documents. Lack of transparent emissions reporting and net-zero commitment constrains score despite absence of acute environmental violations.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

U.S. Manufacturing Onshoring

Announced November 2025 expansion of U.S. manufacturing capabilities at Norwood, Massachusetts facility to enable end-to-end mRNA manufacturing in the United States, reducing import logistics.

Potential reduction in supply-chain carbon from reduced international shipping; completion targeted H1 2027.
Global Manufacturing Network Expansion

Operational manufacturing facilities in Australia, Canada, and UK established under government strategic agreements for domestic mRNA manufacturing and pandemic preparedness.

Localized production may reduce cold-chain logistics emissions but no quantified environmental metrics disclosed.

Social story

Moderna exhibits moderate social performance with notable gaps in executive compensation transparency and workforce diversity disclosure. No union suppression activities or major strikes documented in recent 24 months. Board includes 3 women of 9 directors (33% representation), meeting minimum diversity threshold. Executive leadership diversity not fully disclosed; limited data on CEO-to-worker pay ratio prevents precise calculation but available context suggests elevated ratios. Supply-chain labor practices not discussed in filings; no documented audits of manufacturing partner human-rights compliance. Compensation structure emphasizes stock-based pay aligned with shareholder interests but absolute pay levels not fully transparent. Modest turnover and safety concerns not documented.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Board Diversity Advancement

Board includes 3 women and 5 directors with advanced degrees in scientific fields. Nominating and Corporate Governance Committee actively advancing board succession planning and recruitment of new directors with diverse expertise.

Moderate gender and competency diversity on governance body.
Compensation Alignment with Performance

Executive compensation evolved to enhance alignment with shareholders through pay-for-performance philosophy, reflecting shareholder input on executive compensation proposals.

Alignment of executive incentives with long-term shareholder value creation.

Governance story

Moderna demonstrates solid governance with 8 of 9 directors classified as independent (89% independence), exceeding 75% threshold. Single-class share structure with equal voting rights; no dual-class supermajority concerns. No documented antitrust proceedings, consumer-safety regulatory actions, or financial-fraud consent decrees in provided filings. Lobbying expenditures not disclosed in source documents; unable to assess climate-regulation or consumer-protection deregulation advocacy. Board holds 5 standing committees with clear charter assignments. CEO Stéphane Bancel non-independent by role, appropriate given founder involvement. No active shareholder litigation to block climate proposals identified. Board attendance 99% in 2025. Strong governance infrastructure with room for enhanced transparency on political advocacy and executive compensation metrics.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Board Independence and Oversight

8 of 9 directors are independent. Four standing committees: Audit, Compensation and Talent, Nominating and Corporate Governance, and Product and Technology, with clear charter assignments and regular review of executive performance and strategy.

Strong independent board oversight and committee governance structure.
Capital Allocation Governance

Board provided strategic oversight of capital allocation framework, including $1.5 billion term loan facility approved November 2025 and continued investment in manufacturing and R&D infrastructure aligned with growth strategy.

Disciplined capital deployment framework with board oversight and financial flexibility.
Post-Marketing Compliance

FDA required post-marketing studies for mRNA-1273 COVID vaccine to assess myocarditis/pericarditis risk and outcomes in pregnant women and infants; governance structures in place for regulatory compliance.

Established pharmacovigilance obligations and compliance monitoring.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Moderna Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Moderna Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)